Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Bolt Biotherapeutics, Inc. (BOLT)
|
Add to portfolio |
|
|
|
| Price: |
$4.82
| | Metrics |
| OS: |
38.0
|
M
| |
|
|
| Market cap: |
$183
|
M
| |
|
|
|
Net cash:
|
$13.5
|
M
| |
$0.35
|
per share
|
|
EV:
|
$169
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($68.2)
|
M
| |
|
|
|
EBIT
|
($70.1)
|
M
| |
|
|
| EPS |
($1.41)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 1.3 | 0.2 | 26.0 | 9.4 |
| Revenue growth | 445.5% | -99.1% | 176.0% | |
| Cost of goods sold | 0.0 | 0.0 | 31.2 | 11.6 |
| Gross profit | 1.3 | 0.2 | -5.2 | -2.2 |
| Gross margin | 100.0% | 100.0% | -19.9% | -23.5% |
| Selling, general and administrative | 94.0 | 49.4 | | |
| General and administrative | | | 5.2 | 2.2 |
| EBIT | -104.4 | -72.3 | -31.0 | -11.6 |
| EBIT margin | -8285.2% | -31287.4% | -119.1% | -123.5% |
| Pre-tax income | -98.6 | -60.7 | 0.0 | -11.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% |
| Net income | -98.6 | -60.7 | 0.0 | -11.6 |
| Net margin | -7824.7% | -26289.2% | 0.0% | -123.0% |
| |
| Diluted EPS | ($2.97) | ($30.53) | $0.00 | ($7.02) |
| Shares outstanding (diluted) | 33.2 | 2.0 | 1,993.5 | 1.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|